Importantly, combination treatment with TransCon TLR7/8 Agonist and anti-PD1 antibody yielded greater anti-tumor activity over either agent alone, suggesting that T cell promoting immunotherapies may further potentiate anti-tumor responses in TransCon TLR7/8 Agonist treated tumors. The gene discussed is TLR7; the disease is neoplasm.